Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) EPS (Basic) (2017 - 2025)

UroGen Pharma (URGN) has disclosed EPS (Basic) for 9 consecutive years, with -$0.53 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 34.57% year-over-year to -$0.53, compared with a TTM value of -$3.19 through Dec 2025, down 5.98%, and an annual FY2025 reading of -$3.19, down 7.77% over the prior year.
  • EPS (Basic) was -$0.53 for Q4 2025 at UroGen Pharma, up from -$0.69 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.51 in Q3 2024 and bottomed at -$1.35 in Q3 2021.
  • Average EPS (Basic) over 5 years is -$0.98, with a median of -$1.04 recorded in 2023.
  • The sharpest move saw EPS (Basic) skyrocketed 47.2% in 2023, then crashed 35.29% in 2025.
  • Year by year, EPS (Basic) stood at -$1.27 in 2021, then rose by 1.57% to -$1.25 in 2022, then skyrocketed by 47.2% to -$0.66 in 2023, then decreased by 22.73% to -$0.81 in 2024, then surged by 34.57% to -$0.53 in 2025.
  • Business Quant data shows EPS (Basic) for URGN at -$0.53 in Q4 2025, -$0.69 in Q3 2025, and -$1.05 in Q2 2025.